EUVIMEDEUVIMED entdecken
Leserbrief

Letter: Adropin as a Novel Biomarker of Endothelial Dysfunction in Patients With Preeclampsia

Xiaocong Liu, Yanan Zhang, Yan Li, Cuiping Lv iD

Angiology · 2024

DOI: 10.1177/00033197241235757 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Angiology, 2024. Verfasst von Xiaocong Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Zibo Central Hospital, Zibo, China. Hauptthemen laut MEDLINE: Pre-Eclampsia, Biomarkers, Endothelium, Vascular, Intercellular Signaling Peptides and Proteins. Die Arbeit nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pre-EclampsiaBiomarkersEndothelium, VascularIntercellular Signaling Peptides and ProteinsHumansFemalePregnancyPeptidesBlood Proteins

Substanzen

BiomarkersEnho protein, humanIntercellular Signaling Peptides and ProteinsPeptidesBlood Proteins

Autor:innen und Institutionen

  • Department of Clinical Laboratory, Zibo Central Hospital, Zibo, China.
  • Department of Clinical Laboratory, Zibo Occupational Disease Prevention and Control Hospital, Zibo, China.
  • Department of Jahwa ward, Liaocheng Dongchangfu District Maternal and Child Health Hospital, Liaocheng, China.

ORCID-Profile: Cuiping Lv

Zitieren

APA

Liu, X., Zhang, Y., Li, Y., & Lv, C. (2024). Letter: Adropin as a Novel Biomarker of Endothelial Dysfunction in Patients With Preeclampsia. Angiology. https://doi.org/10.1177/00033197241235757

Vancouver

Liu X, Zhang Y, Li Y, Lv C. Letter: Adropin as a Novel Biomarker of Endothelial Dysfunction in Patients With Preeclampsia. Angiology. 2024. doi:10.1177/00033197241235757

BibTeX
@article{Liu2024,
  author = {Liu, Xiaocong and Zhang, Yanan and Li, Yan and Lv, Cuiping},
  title = {Letter: Adropin as a Novel Biomarker of Endothelial Dysfunction in Patients With Preeclampsia},
  journal = {Angiology},
  year = {2024},
  doi = {10.1177/00033197241235757}
}
Kostenlos starten →